Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines.
Currently, there is no completely effective therapy available for metastatic phaeochromocytomas (PCCs) and paragangliomas. In this study, we explore new molecular targeted therapies for these tumours, using one more benign (mouse phaeochromocytoma cell (MPC)) and one more malignant (mouse tumour tis...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2012
|
| _version_ | 1797098547166838784 |
|---|---|
| author | Nölting, S Garcia, E Alusi, G Giubellino, A Pacak, K Korbonits, M Grossman, AB |
| author_facet | Nölting, S Garcia, E Alusi, G Giubellino, A Pacak, K Korbonits, M Grossman, AB |
| author_sort | Nölting, S |
| collection | OXFORD |
| description | Currently, there is no completely effective therapy available for metastatic phaeochromocytomas (PCCs) and paragangliomas. In this study, we explore new molecular targeted therapies for these tumours, using one more benign (mouse phaeochromocytoma cell (MPC)) and one more malignant (mouse tumour tissue (MTT)) mouse PCC cell line - both generated from heterozygous neurofibromin 1 knockout mice. Several PCC-promoting gene mutations have been associated with aberrant activation of PI3K/AKT, mTORC1 and RAS/RAF/ERK signalling. We therefore investigated different agents that interfere specifically with these pathways, including antagonism of the IGF1 receptor by NVP-AEW541. We found that NVP-AEW541 significantly reduced MPC and MTT cell viability at relatively high doses but led to a compensatory up-regulation of ERK and mTORC1 signalling at suboptimal doses while PI3K/AKT inhibition remained stable. We subsequently investigated the effect of the dual PI3K/mTORC1/2 inhibitor NVP-BEZ235, which led to a significant decrease of MPC and MTT cell viability at doses below 50 nM but again increased ERK signalling. Accordingly, we next examined the combination of NVP-BEZ235 with the established agent lovastatin, as this has been described to inhibit ERK signalling. Lovastatin alone significantly reduced MPC and MTT cell viability at therapeutically relevant doses and inhibited both ERK and AKT signalling, but increased mTORC1/p70S6K signalling. Combination treatment with NVP-BEZ235 and lovastatin showed a significant additive effect in MPC and MTT cells and resulted in inhibition of both AKT and mTORC1/p70S6K signalling without ERK up-regulation. Simultaneous inhibition of PI3K/AKT, mTORC1/2 and ERK signalling suggests a novel therapeutic approach for malignant PCCs. |
| first_indexed | 2024-03-07T05:11:09Z |
| format | Journal article |
| id | oxford-uuid:db96ce08-42e4-4805-a4ed-06116b8bf80f |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T05:11:09Z |
| publishDate | 2012 |
| record_format | dspace |
| spelling | oxford-uuid:db96ce08-42e4-4805-a4ed-06116b8bf80f2022-03-27T09:11:41ZCombined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:db96ce08-42e4-4805-a4ed-06116b8bf80fEnglishSymplectic Elements at Oxford2012Nölting, SGarcia, EAlusi, GGiubellino, APacak, KKorbonits, MGrossman, ABCurrently, there is no completely effective therapy available for metastatic phaeochromocytomas (PCCs) and paragangliomas. In this study, we explore new molecular targeted therapies for these tumours, using one more benign (mouse phaeochromocytoma cell (MPC)) and one more malignant (mouse tumour tissue (MTT)) mouse PCC cell line - both generated from heterozygous neurofibromin 1 knockout mice. Several PCC-promoting gene mutations have been associated with aberrant activation of PI3K/AKT, mTORC1 and RAS/RAF/ERK signalling. We therefore investigated different agents that interfere specifically with these pathways, including antagonism of the IGF1 receptor by NVP-AEW541. We found that NVP-AEW541 significantly reduced MPC and MTT cell viability at relatively high doses but led to a compensatory up-regulation of ERK and mTORC1 signalling at suboptimal doses while PI3K/AKT inhibition remained stable. We subsequently investigated the effect of the dual PI3K/mTORC1/2 inhibitor NVP-BEZ235, which led to a significant decrease of MPC and MTT cell viability at doses below 50 nM but again increased ERK signalling. Accordingly, we next examined the combination of NVP-BEZ235 with the established agent lovastatin, as this has been described to inhibit ERK signalling. Lovastatin alone significantly reduced MPC and MTT cell viability at therapeutically relevant doses and inhibited both ERK and AKT signalling, but increased mTORC1/p70S6K signalling. Combination treatment with NVP-BEZ235 and lovastatin showed a significant additive effect in MPC and MTT cells and resulted in inhibition of both AKT and mTORC1/p70S6K signalling without ERK up-regulation. Simultaneous inhibition of PI3K/AKT, mTORC1/2 and ERK signalling suggests a novel therapeutic approach for malignant PCCs. |
| spellingShingle | Nölting, S Garcia, E Alusi, G Giubellino, A Pacak, K Korbonits, M Grossman, AB Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines. |
| title | Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines. |
| title_full | Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines. |
| title_fullStr | Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines. |
| title_full_unstemmed | Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines. |
| title_short | Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines. |
| title_sort | combined blockade of signalling pathways shows marked anti tumour potential in phaeochromocytoma cell lines |
| work_keys_str_mv | AT noltings combinedblockadeofsignallingpathwaysshowsmarkedantitumourpotentialinphaeochromocytomacelllines AT garciae combinedblockadeofsignallingpathwaysshowsmarkedantitumourpotentialinphaeochromocytomacelllines AT alusig combinedblockadeofsignallingpathwaysshowsmarkedantitumourpotentialinphaeochromocytomacelllines AT giubellinoa combinedblockadeofsignallingpathwaysshowsmarkedantitumourpotentialinphaeochromocytomacelllines AT pacakk combinedblockadeofsignallingpathwaysshowsmarkedantitumourpotentialinphaeochromocytomacelllines AT korbonitsm combinedblockadeofsignallingpathwaysshowsmarkedantitumourpotentialinphaeochromocytomacelllines AT grossmanab combinedblockadeofsignallingpathwaysshowsmarkedantitumourpotentialinphaeochromocytomacelllines |